CN102791267A - 消炎镇痛外用贴剂 - Google Patents

消炎镇痛外用贴剂 Download PDF

Info

Publication number
CN102791267A
CN102791267A CN2011800054379A CN201180005437A CN102791267A CN 102791267 A CN102791267 A CN 102791267A CN 2011800054379 A CN2011800054379 A CN 2011800054379A CN 201180005437 A CN201180005437 A CN 201180005437A CN 102791267 A CN102791267 A CN 102791267A
Authority
CN
China
Prior art keywords
weight
external use
diclofenac
hydroxyethyl pyrrolidine
diclofenac hydroxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011800054379A
Other languages
English (en)
Other versions
CN102791267B (zh
Inventor
柴田大树
马渕佑一郎
服部健一
镰仓高志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IBSA Institut Biochimique SA
Teikoku Seiyaku Co Ltd
Original Assignee
IBSA Institut Biochimique SA
Teikoku Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IBSA Institut Biochimique SA, Teikoku Seiyaku Co Ltd filed Critical IBSA Institut Biochimique SA
Publication of CN102791267A publication Critical patent/CN102791267A/zh
Application granted granted Critical
Publication of CN102791267B publication Critical patent/CN102791267B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/10Methods of surface bonding and/or assembly therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种经皮吸收性优异、且皮肤刺激性小、并且主药稳定性也优异的含有双氯芬酸羟基乙基吡咯烷的外用贴剂,其特征在于,其为在支撑体上层叠粘合剂层而成的贴剂,该粘合剂层以苯乙烯·异戊二烯·苯乙烯嵌段共聚物5~50重量%、粘合赋予树脂20~50重量%、软化剂5~70重量%、和选自N-甲基-2-吡咯烷酮、丙二醇及二甲基亚砜中的1种或者2种以上的增溶剂0.5~20重量%为必须成分,作为有效成分配合双氯芬酸羟基乙基吡咯烷0.5~20重量%而成。

Description

消炎镇痛外用贴剂
技术领域
本发明涉及双氯芬酸羟基乙基吡咯烷(diclofenac hydroxyethylpyrrolidine)的经皮吸收性及主药稳定性优异、且对皮肤的刺激性低的含有双氯芬酸羟基乙基吡咯烷的油性贴剂。
背景技术
作为双氯芬酸盐的一种的双氯芬酸羟基乙基吡咯烷比双氯芬酸钠的融点低,是适于经皮吸收制剂的药物(专利文献1)。此外由于双氯芬酸羟基乙基吡咯烷与双氯芬酸钠相比,水溶性优异,与水性基剂的相容性好,因而从以往就在研究含有双氯芬酸羟基乙基吡咯烷的巴布剂(专利文献2)。但是,一般而言,巴布剂存在药物的经皮吸收性不充分、对皮肤的粘合性低等问题。
专利文献1 : 日本特开昭63-152372号
专利文献2 : 日本特开平6-305958号。
发明内容
发明要解决的技术问题
本发明解决了上述问题,提供一种经皮吸收性优异、且皮肤刺激性小、并且主药稳定性也优异的含有双氯芬酸羟基乙基吡咯烷的外用贴剂。
解决问题的技术手段
本发明人等为了解决上述课题,进行了深入研究,结果发现,通过制备配合主药成分与特定的增溶剂而形成的油性贴剂,可以解决上述课题,从而完成了本发明。
即,本发明为一种含有双氯芬酸羟基乙基吡咯烷的油性外用贴剂,其特征在于,其为在支撑体上层叠粘合剂层而成的贴剂,该粘合剂层以苯乙烯・异戊二烯・苯乙烯嵌段共聚物5~50重量%、粘合赋予树脂20~50重量%、软化剂5~70重量%、和选自N-甲基-2-吡咯烷酮、丙二醇及二甲基亚砜中的1种或者2种以上的增溶剂0.5~20重量%为必须成分,作为有效成分配合双氯芬酸羟基乙基吡咯烷0.5~20重量%而成。
发明的效果
本发明的外用贴剂通过采用上述构成,可以获得如下效果:提供双氯芬酸羟基乙基吡咯烷的经皮吸收性优异、且皮肤刺激性小、并且保存稳定性也优异的贴剂等。
附图说明
图1为表示试验例1的体外(in vitro)大鼠皮肤透过性试验的结果的图。
具体实施方式
本发明中的双氯芬酸羟基乙基吡咯烷的配合量为0.5~20重量%,优选为1~10重量%。双氯芬酸羟基乙基吡咯烷的配合量为0.5重量%以下时,得不到充分的药效,相反配合20重量%以上时,制剂中的主药成分结晶等,对制剂物性产生不良影响。
作为本发明中的双氯芬酸羟基乙基吡咯烷的增溶剂,选择N-甲基-2-吡咯烷酮、丙二醇及二甲基亚砜中的1种或2种以上使用。其中,特别优选丙二醇。其配合量为0.5~20重量%,优选为1~10重量%。配合量为0.5重量%以下时,主药成分在制剂中无法充分溶解,结果导致经皮吸收性降低、或者主药成分在制剂中结晶等制剂物性的恶化。另外配合20重量%以上时,皮肤刺激性上升,基剂的凝集力降低等,对制剂物性产生不良影响。
本发明的粘合剂层中使用的苯乙烯・异戊二烯・苯乙烯嵌段共聚物的配合量为5~50重量%,优选为10~30重量%。为5重量%以下时,产生粘合层的凝集力不充分、基剂残留在肌肤上的问题,50重量%以上时,凝集力过高,导致粘合力的降低、或捏合操作的降低,因而不优选。
通常,粘合赋予树脂通过与苯乙烯・异戊二烯・苯乙烯嵌段共聚物混合,从而赋予对皮肤的粘合性,其配合量为20~50重量%,更优选为20~35重量%。粘合赋予树脂的配合量不足20重量%时,作为外用贴剂的粘合物性变差,超过50重量%时,粘合力变得过强,从皮肤上剥离时产生物理性的皮肤刺激,因而不优选。作为本发明中使用的粘合赋予树脂,可以选择松香系树脂、萜烯系树脂、石油系树脂、酚系树脂、二甲苯系树脂等中的1种或2种以上使用,特别优选氢化松香甘油酯和脂环族饱和烃树脂。
本发明的粘合剂层中可以进一步配合液体石蜡、凡士林等油脂类,聚丁烯、聚异丁烯、聚异戊二烯等液态橡胶类等的软化剂,其配合量为5~70重量%,更优选为20~60重量%。特别优选液体石蜡、聚丁烯。
本发明中,为了提高双氯芬酸羟基乙基吡咯烷的经皮吸收性,可以添加经皮吸收促进剂等。作为经皮吸收促进剂,具体而言可以列举出,肉豆蔻酸异丙酯、己二酸二异丙酯等脂肪酸酯,异硬脂酸、油酸、肉豆蔻酸等高级脂肪酸,二异丙醇胺、三乙醇胺等胺类,单油酸脱水山梨糖醇酯、聚桂醇(lauromacrogol)等表面活性剂等。
本发明的粘合剂层中可以配合酸性高分子。本发明的油性贴剂中添加酸性高分子时,羟基乙基吡咯烷盐的一部分或全部从双氯芬酸羟基乙基吡咯烷中脱去,结果生成双氯芬酸游离体,该药物的经皮吸收性被改善。作为本发明中的酸性高分子,特别优选聚丙烯酸,其配合量为0.1~10重量%,更优选为0.1~5重量%。
另外作为本发明的基剂成分,为了调整基剂的粘接性・稳定性,可以根据需要适当选择、添加通常在制造贴剂时使用的成分。具体而言,可以适当适量含有聚乙烯吡咯烷酮、聚乙烯吡咯烷酮/醋酸乙烯酯共聚物等吸水性高分子、二酸化钛、二氧化硅类等无机充填剂、及二丁基羟基甲苯等抗氧化剂等。
本发明的油性贴剂中的支持体理想的是,充满柔软性、伸缩性的材料,可以列举出聚酯制的织布、无纺布、低密度高分子薄膜等,不限定于这些,可以选择适当材料。
本发明中使用的剥离衬垫使用聚对苯二甲酸乙二醇酯、聚丙烯、纸等。剥离衬垫为了使其剥离力适当,可根据需要进行硅处理。
本发明的油性贴剂例如可以通过以下的方法制造。使双氯芬酸羟基乙基吡咯烷在前述增溶剂中加热溶解,制备药液。另外,将苯乙烯・异戊二烯・苯乙烯嵌段共聚物、软化剂(例如聚丁烯、液体石蜡)、粘合赋予树脂、及根据需要的抗氧化剂、酸性高分子等加热搅拌进行混合。将药液添加到该粘合基剂中,通过搅拌混合直到变均匀,从而得到粘合剂层,通过已知的方法将该得到的粘合剂层涂布于衬垫上,使其与支持体贴合后,裁切成适当大小和形状,从而可以获得本发明的外用贴剂。这种情况下,粘合剂层的涂布量为50~400g/m2即足够,优选为100~200g/m2
实施例
接着,举出实施例更具体地说明本发明,但本发明不受以下实施例的限定。需要说明的是,实施例中的数值在无特别说明时,表示“重量%”。
实施例
根据表1中所示的处方,按照上述的制造法制作各实施例的油性贴剂。
[表1]
Figure 80151DEST_PATH_IMAGE001
比较例
参考专利文献2的实施例1,制作表2中所示比较例1的外用贴剂(巴布剂)。
[表2]
组成/比较例 比较例1
双氯芬酸羟基乙基吡咯烷 1.3
聚丙烯酸钠 4
羧甲基纤维素钠 3
明胶 2
聚乙烯吡咯烷酮 2
1,3-丁二醇 20
D-山梨醇液体 20
高岭土 5
氧化钛 0.5
氢氧化铝 0.8
酒石酸 0.3
对羟基苯甲酸甲酯 0.1
对羟基苯甲酸丙酯 0.05
精制水 适量
合计 100
试验例1:体外(in vitro)大鼠皮肤透过性试验
为了研究本发明的油性贴剂中的双氯芬酸羟基乙基吡咯烷的经皮吸收性,对于实施例1~4、及比较例1,进行了大鼠中的体外(in vitro)皮肤透过性试验。将Wistar系大鼠的腹部摘出皮肤装入Franz型扩散池中,贴附裁切成圆形(φ14mm)的各试验制剂。将接收侧充满磷酸缓冲生理食盐水,在水套中回流37℃的温水。经时对接收液进行取样,通过液相色谱法测定透过皮肤的双氯芬酸羟基乙基吡咯烷量。
其结果示于图1。
试验例2:兔子皮肤一次刺激性试验
对于实施例1~4及比较例1的皮肤一次刺激性,通过使用兔子的Draize法进行试验。将各试验制剂贴附在兔子背部的健康皮肤及损伤皮肤上24小时,按照表3的判定基准,目视判定剥离1小时、24小时、48小时后的皮肤症状,计算出各试验制剂的刺激指数。刺激指数的判定基准示于表3-1,测定结果示于表3-2。
[表3-1]
Figure 997291DEST_PATH_IMAGE002
[表3-2]
试验制剂 实施例1 实施例2 实施例3 实施例4 比较例1
刺激指数 1.2 1.2 1.3 1.0 1.2
试验例3:稳定性试验
对于实施例1~4,评价贴剂中的药物稳定性。将各试验制剂在40℃下保存6个月时间,然后通过液相色谱法测定采取的样品的药物浓度,将试验开始前的各制剂中的双氯芬酸羟基乙基吡咯烷含量作为初始值(100%),计算保存后的各制剂的药物残存率(相对于初始%)。其结果示于表4。
[表4]
保存条件 实施例1 实施例2 实施例3 实施例4
初始 100.0 100.0 100.0 100.0
40℃-6个月 98.9 98.1 97.9 98.1
根据上述各试验结果,判明了本发明的油性贴剂为与比较例的巴布剂同等水平的安全性高的制剂,且与巴布剂相比,为显示出非常高的经皮吸收性的制剂。另外判明了在主药的稳定性方面也非常优异。即本发明的含有双氯芬酸羟基乙基吡咯烷的油性外用贴剂是兼具优异的经皮吸收性、安全性和主药稳定性的外用贴剂。

Claims (2)

1.一种含有双氯芬酸羟基乙基吡咯烷的油性外用贴剂,其为在支撑体上层叠粘合剂层而成的贴剂,该粘合剂层以苯乙烯・异戊二烯・苯乙烯嵌段共聚物5~50重量%、粘合赋予树脂20~50重量%、软化剂5~70重量%、和选自N-甲基-2-吡咯烷酮、丙二醇及二甲基亚砜中的1种或者2种以上的增溶剂0.5~20重量%为必须成分,作为有效成分配合双氯芬酸羟基乙基吡咯烷0.5~20重量%而成。
2.根据权利要求1所述的含有双氯芬酸羟基乙基吡咯烷的油性外用贴剂,其特征在于,该粘合剂层进一步含有酸性高分子。
CN201180005437.9A 2010-01-07 2011-01-05 消炎镇痛外用贴剂 Active CN102791267B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010002188 2010-01-07
JP2010-002188 2010-01-07
PCT/JP2011/050021 WO2011083787A1 (ja) 2010-01-07 2011-01-05 消炎鎮痛外用貼付剤

Publications (2)

Publication Number Publication Date
CN102791267A true CN102791267A (zh) 2012-11-21
CN102791267B CN102791267B (zh) 2015-06-10

Family

ID=44305523

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180005437.9A Active CN102791267B (zh) 2010-01-07 2011-01-05 消炎镇痛外用贴剂

Country Status (15)

Country Link
US (1) US8657798B2 (zh)
EP (1) EP2524692B1 (zh)
JP (1) JP5748671B2 (zh)
KR (1) KR101797787B1 (zh)
CN (1) CN102791267B (zh)
AU (1) AU2011204228B2 (zh)
CA (1) CA2786233C (zh)
DK (1) DK2524692T3 (zh)
ES (1) ES2503215T3 (zh)
HK (1) HK1178459A1 (zh)
PL (1) PL2524692T3 (zh)
PT (1) PT2524692E (zh)
SG (1) SG182391A1 (zh)
TW (1) TWI482645B (zh)
WO (1) WO2011083787A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
EP2708229B1 (en) 2011-05-10 2019-07-31 Itochu Chemical Frontier Corporation Non-aqueous patch
US9925264B2 (en) 2011-05-10 2018-03-27 Itochu Chemical Frontier Corporation Non-aqueous patch
WO2013046335A1 (ja) 2011-09-27 2013-04-04 伊藤忠ケミカルフロンティア株式会社 非水性貼付剤
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP2015098439A (ja) * 2012-03-07 2015-05-28 株式会社 ケイ・エム トランスダーム 貼付剤
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
ES2656949T3 (es) * 2012-06-20 2018-03-01 Hisamitsu Pharmaceutical Co., Inc. Parche para la piel
JP6150240B2 (ja) * 2012-09-21 2017-06-21 東洋製罐株式会社 包装材およびそれを用いてなる包装構造
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US11872320B2 (en) 2021-02-25 2024-01-16 Hisamitsu Pharmaceutical Co., Inc. Method for treating osteoarthritis

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378848A (en) * 1979-10-02 1983-04-05 Fmc Corporation Method and apparatus for controlling subsea well template production systems
EP0372527A1 (en) * 1988-12-09 1990-06-13 Altergon S.A. Topical compositions containing diclofenac
CN1462187A (zh) * 2001-05-23 2003-12-17 株式会社脱苦海 供局部使用的止痛抗炎贴剂
US20040037872A1 (en) * 2000-09-18 2004-02-26 Liebschutz Isabelle Francine Tropical composition
CN1489996A (zh) * 2003-06-25 2004-04-21 蚌埠丰原医药科技发展有限公司 双氯芬酸钠贴剂及其制备方法
CN101080219A (zh) * 2004-12-15 2007-11-28 帝国制药株式会社 含依托芬那酯的外用贴剂
CN101119716A (zh) * 2005-02-28 2008-02-06 帝国制药株式会社 含有氟比洛芬的外用贴剂
JP2008143866A (ja) * 2006-12-12 2008-06-26 Hisamitsu Pharmaceut Co Inc 粘着剤及び貼付剤
CN101530401A (zh) * 2008-03-12 2009-09-16 中山市中健药物研究所有限公司 一种用于治疗急慢性炎性疼痛的复方透皮贴片
WO2009154148A1 (ja) * 2008-06-16 2009-12-23 帝國製薬株式会社 消炎鎮痛外用剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280426A (ja) 1985-06-04 1986-12-11 Ikeda Mohandou:Kk 消炎鎮痛用貼付剤
IT1228242B (it) 1986-11-13 1991-06-05 Ricerfarma Srl Milano Sale del diclofenac con idrossietilpirrolidina e composizioni farmaceutiche che lo contengono
JP3146002B2 (ja) * 1990-11-09 2001-03-12 帝國製薬株式会社 経皮投与製剤
JP3526887B2 (ja) 1993-04-23 2004-05-17 帝國製薬株式会社 消炎鎮痛外用貼付剤
JPH08295624A (ja) * 1995-04-26 1996-11-12 Read Chem Kk プラスター基剤、その製造方法、該基剤を使用した外用貼 付剤
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6914169B1 (en) * 2000-05-19 2005-07-05 Hisamitsu Pharmaceutical., Inc. Patch agent
JP4178323B2 (ja) 2003-12-13 2008-11-12 文子 吉本 第何週目か分かるカレンダー。
PT2143445E (pt) * 2007-04-23 2013-12-13 Hisamitsu Pharmaceutical Co Emplastro medicamentoso

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378848A (en) * 1979-10-02 1983-04-05 Fmc Corporation Method and apparatus for controlling subsea well template production systems
EP0372527A1 (en) * 1988-12-09 1990-06-13 Altergon S.A. Topical compositions containing diclofenac
US20040037872A1 (en) * 2000-09-18 2004-02-26 Liebschutz Isabelle Francine Tropical composition
CN1462187A (zh) * 2001-05-23 2003-12-17 株式会社脱苦海 供局部使用的止痛抗炎贴剂
CN1489996A (zh) * 2003-06-25 2004-04-21 蚌埠丰原医药科技发展有限公司 双氯芬酸钠贴剂及其制备方法
CN101080219A (zh) * 2004-12-15 2007-11-28 帝国制药株式会社 含依托芬那酯的外用贴剂
CN101119716A (zh) * 2005-02-28 2008-02-06 帝国制药株式会社 含有氟比洛芬的外用贴剂
JP2008143866A (ja) * 2006-12-12 2008-06-26 Hisamitsu Pharmaceut Co Inc 粘着剤及び貼付剤
CN101530401A (zh) * 2008-03-12 2009-09-16 中山市中健药物研究所有限公司 一种用于治疗急慢性炎性疼痛的复方透皮贴片
WO2009154148A1 (ja) * 2008-06-16 2009-12-23 帝國製薬株式会社 消炎鎮痛外用剤

Also Published As

Publication number Publication date
EP2524692A1 (en) 2012-11-21
DK2524692T3 (da) 2014-10-20
PL2524692T3 (pl) 2015-03-31
KR101797787B1 (ko) 2017-11-15
KR20120101720A (ko) 2012-09-14
JPWO2011083787A1 (ja) 2013-05-13
JP5748671B2 (ja) 2015-07-15
TWI482645B (zh) 2015-05-01
CN102791267B (zh) 2015-06-10
AU2011204228B2 (en) 2014-03-27
EP2524692A4 (en) 2013-07-31
US20120283671A1 (en) 2012-11-08
WO2011083787A1 (ja) 2011-07-14
TW201141545A (en) 2011-12-01
EP2524692B1 (en) 2014-09-10
HK1178459A1 (zh) 2013-09-13
AU2011204228A1 (en) 2012-07-19
US8657798B2 (en) 2014-02-25
SG182391A1 (en) 2012-08-30
CA2786233C (en) 2018-01-02
ES2503215T3 (es) 2014-10-06
PT2524692E (pt) 2014-09-18
CA2786233A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
CN102791267B (zh) 消炎镇痛外用贴剂
EP2716287B1 (en) Ropinirole-containing adhesive skin patch and packaged product thereof
EP2716286B1 (en) Ropinirole-containing adhesive patch and packaging therefor
JP6064252B2 (ja) そう痒症改善経皮吸収貼付剤
JP2011020997A (ja) 外用貼付剤
JP2004339114A (ja) エストロゲン及び/又はプロゲストゲン含有外用貼付剤
JP5421063B2 (ja) ジクロフェナクナトリウム含有水性貼付剤
JP5576573B2 (ja) 貼付剤
KR20180121352A (ko) 경피 흡수형 제제
WO2005102306A1 (ja) 消炎鎮痛貼付剤
WO2020262057A1 (ja) 水性貼付剤
WO2014068600A1 (en) Stable transdermal pharmaceutical drug delivery system comprising diclofenac
JP7399633B2 (ja) 経皮吸収型製剤の製造方法
JP5192722B2 (ja) 外用貼付剤
JP2887548B2 (ja) 使用性の改善された含水性皮膚外用貼付剤
TW201813635A (zh) 貼附劑
JP6002055B2 (ja) 貼付剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1178459

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1178459

Country of ref document: HK